Chemotherapy

Cisplatin/Epinephrine Demonstrates Versatility In Controlling Solid Tumors

Published in Cancer Weekly, November 27th, 2001

Study results contained in three presentations made by Matrix Pharmaceutical, Inc., at the European Congress on Clinical Oncology (ECCO) meeting in Lisbon, Portugal in late October 2001 helped demonstrate the potential versatility of IntraDose (cisplatin/epinephrine) Injectable Gel in controlling solid tumors.

Final Phase II study results of inoperable primary liver cancer were presented for the first time. Additionally, data from two Phase III studies of IntraDose in head and neck cancer and Phase II studies of metastatic melanoma were presented. IntraDose is a novel drug system designed to provide local control of solid tumors through direct injection while reducing...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-11-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry